Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$671.64 ▲ +120.43
(+21.85%)
MKT CAP: $43.42B • VOL: 1.98M
52W L $501 52W H $770
IDXX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.30B | $3.90B | $3.66B |
| YoY Revenue Growth % | +10.4% | +6.5% | — |
| Gross Profit | $2.66B | $2.38B | — |
| Gross Margin % | 61.8% | 61.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.36B | $1.13B | $1.10B |
| Operating Margin % | 31.6% | 29.0% | 30.0% |
| Net Income (GAAP) | $1.06B | $887.9M | $845.0M |
| EBITDA (Normalized) | $1.46B | $1.23B | $1.23B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.18B | $929.0M | $906.5M |
| Capital Expenditures (CapEx) | $124.7M | $120.9M | $164.7M |
| Free Cash Flow (FCF) | $1.06B | $808.1M | $741.8M |
| FCF Margin % | 24.6% | 20.7% | 20.3% |
| Return on Invested Capital (ROIC %) | 59.7% | 50.7% | 5.7% |
| Cash & Short-Term Equivalents | $180.1M | $288.3M | — |
| Total Debt (Short + Long Term) | $374.8M | $449.8M | $5.84B |
| Total Stockholders' Equity | $1.61B | $1.60B | $11.98B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IDXX.